1000 Mylan Boulevard
Mylan is a global pharmaceutical company committed to setting new standards in healthcare. Working together around the world to provide 7 billion people access to high quality medicine, Mylan innovates to satisfy unmet needs; make reliability and service excellence a habit; do what's right, not what's easy; and impact the future through passionate global leadership
Founders: Milan Puskar, and Don Panoz
CEO: Heather Bresch
CFO: Neil Dimick
988 articles with Mylan
Mylan N.V. (Nasdaq: MYL) today announced that its shareholders overwhelmingly voted to approve the proposed transaction combining Mylan and Upjohn, a division of Pfizer, at the company's extraordinary general meeting of shareholders.
Mylan N.V. (NASDAQ: MYL) and Lupin Limited (Lupin) today announced that the European Commission (EC) has granted marketing authorization for Nepexto ® , a biosimilar to Enbrel ® (etanercept), for all indications of the reference product including rheumatoid arthritis, juvenile idiopathic art
June 1, 2020 12:30 UTC - First neurotoxin formulation to be developed as a potential biosimilar product to BOTOX ® , potentially giving Mylan access to 14 indications upon approval - - $30 million milestone payable to Revance from Mylan -
Global pharmaceutical company Mylan N.V. (NASDAQ: MYL) today announced that Executive Chairman Robert J. Coury and President Rajiv Malik will present at the 2020 RBC Capital Markets' Virtual Global Healthcare Conference on Tuesday, May 19, 2020 at 8 a.m. ET.
Mylan and Gilead Sciences sign global collaboration agreement for the commercialization of remdesivir in 127 low- and middle-income countries
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for May 12, 2020.
Comprehensive report includes a look at Mylan's historical impact on patients, employees, the environment, global public health and the community
The Mylan N.V. (NASDAQ: MYL) Board of Directors today announced the appointment of Robert J. Coury , previously chairman of the Mylan Board, to the position of executive chairman of Mylan. Given the unprecedented current operating environment due to the COVID-19 pandemic, the extensive ongoing activity
Due to global impact of COVID-19 pandemic, transaction now expected to close in the second half of 2020 and Mylan's EGM moved to June 30
The delays, particularly in the regulatory review process, have caused the merger completion to be pushed back to the second half of this year.
A summary of daily biopharma industry news. Please check out stories that are trending on March 26, 2020.
Mylan Ramps Up U.S. Manufacturing of Hydroxychloroquine Sulfate Tablets to Meet Potential COVID-19 Patient Needs
Mylan N.V. (NASDAQ: MYL) today announced its continued commitment to do its part in support of public health needs amidst the evolving COVID-19 pandemic. The company continues to focus its efforts on protecting our employees, producing critically needed medications, and turning our scientific and operational
Mylan N.V. announced that the U.S. District Court of New Jersey found the device patent claims asserted by Sanofi against Mylan's insulin glargine product not infringed and invalid for lack of written description.
U.S. FDA Accepts Biologics License Application (BLA) for Mylan and Biocon's Proposed Biosimilar Bevacizumab for Review
Mylan N.V. (NASDAQ: MYL) and Biocon Ltd. (BSE code: 532523, NSE: BIOCON) today announced that the U.S. Food and Drug Administration (FDA) has accepted Mylan's Biologics License Application (BLA) for MYL-1402O, a proposed biosimilar to Avastin® (bevacizumab), for review under the 351(k) pathway.
Pfizer's Upjohn Division CFO Sanjeev Narula selected for leadership role at combined company
13 Inaugural Directors Bring Wide-Ranging Experience, Expertise and a Focus on Driving Shareholder Value
Global pharmaceutical company Mylan N.V. (NASDAQ: MYL) today announced that it will release its fourth quarter and full year 2019 financial results, as well as its 2020 financial guidance, on Thursday, Feb. 27, after the close of the U.S. financial markets.
While the conditions surrounding the City by the Bay are in a negative light, there is still a significant amount of positive news coming out of the conference.
Mylan Initiates Voluntary Nationwide Recall of Three Lots of Nizatidine Capsules, USP, Due to the Detection of Trace Amounts of NDMA Impurity Found in the Active Pharmaceutical Ingredient Manufactured by Solara Active Pharma Scien
Mylan N.V. announced that its U.S. based Mylan Pharmaceuticals business is conducting a voluntary nationwide recall, to the consumer level, of three lots of Nizatidine Capsules, USP.
Global pharmaceutical company Mylan N.V. announced that Chairman Robert J. Coury, together with Upjohn's Group President Michael Goettler and Mylan's President Rajiv Malik, will present at the 38th Annual J.P. Morgan Healthcare Conference in San Francisco, Calif., on Wednesday, Jan. 15, 2020 at 8:30 a.m. PT / 11:30 a.m. ET.